Skip to main content

Table 5 Multivariate logistic analysis of the relationship between medications used with statins and high MDA-LDL level

From: Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease

 

Adjusted OR (95% CI)

p

ACE-Is or ARBs

1.29 (0.61–2.78)

0.508

β-Blockers

1.04 (0.51–2.12)

0.923

Ca channel blockers

1.23 (0.62–2.45)

0.548

Metformin

0.48 (0.24–0.94)

0.032

Pioglitazone

0.61 (0.28–1.28)

0.190

α-Glucosidase inhibitors

0.43 (0.21–0.87)

0.018

Sulfonylurea

1.65 (0.76–3.66)

0.205

Insulin therapy

0.51 (0.21–1.20)

0.124

Other variables

  

 LDL cholesterol

241.6 (22.0–3289.8)*

<0.0001

 Triglycerides

12.95 (2.02–93.09)*

0.007

 HDL cholesterol

0.10 (0.00–0.98)*

0.048

 Adiponectin

1.18 (0.19–7.12)*

0.859

  1. Abbreviations: ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, CI confidence interval; HDL high-density lipoprotein, LDL low-density lipoprotein, MDA-LDL malondialdehyde-modified LDL, OR odds ratio.
  2. Multivariate logistic regression analysis was performed with an adjustment for all indicated medicines and the levels of LDL cholesterol, triglycerides, HDL cholesterol, and adiponectin. A high MDA-LDL level was defined by a median value of >91 U/L.
  3. *Range OR (95% CI).
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us